Follow Binaytara on FacebookFollow Binaytara on XFollow Binaytara on LinkedinFollow Binaytara on BlueskyFollow Binaytara on Instagram
Binaytara logo
  • About Us
  • CME Conferences
  • Funding Opportunities
  • Projects
  • Get Involved
  • News
  • GALA 2027
Friday, November 6, 2026
The Cancer News

AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER

All Articles
Cancer Education
  • Resources for Cancer Patients
Perspectives
Clinical Breakthroughs & Research
Health Equity
About Us
  • Contributors
  • Ethics and Disclosure Policy
  • Editorial Standards & Corrections Policy
Article Submission
The Cancer News>Cancer Education>New Targets in Squamous NSCLC: Old Mechanisms, Novel Approaches, and Two Phase 3 Trials Worth Watching

New Targets in Squamous NSCLC: Old Mechanisms, Novel Approaches, and Two Phase 3 Trials Worth Watching

New Targets in Squamous NSCLC: Old Mechanisms, Novel Approaches, and Two Phase 3 Trials Worth Watching

Browse by Topics

Cancer EducationPerspectivesHealth EquityHealth PolicyResources for Cancer PatientsResearch
More from Cancer Education
Small Cell Lung Cancer in 2026: Consolidation IO Is Standard, Tarlatamab Has Full Approval, and the Maintenance Era Has Arrived

Small Cell Lung Cancer in 2026: Consolidation IO Is Standard, Tarlatamab Has Full Approval, and the Maintenance Era Has Arrived

November 4, 2026

When a PARP Inhibitor Works but the Body Cannot Tolerate It: Severe Niraparib Toxicity in BRCA1-Mutated Ovarian Cancer

When a PARP Inhibitor Works but the Body Cannot Tolerate It: Severe Niraparib Toxicity in BRCA1-Mutated Ovarian Cancer

November 3, 2026

Upper GI Cancer Updates: Perioperative Immunotherapy and New HER2-Directed Options

Upper GI Cancer Updates: Perioperative Immunotherapy and New HER2-Directed Options

November 3, 2026

Milk Thistle and Cancer: Why the Warning Label Exists

Milk Thistle and Cancer: Why the Warning Label Exists

November 2, 2026

Safe Delivery of CAR-T and Bispecific Therapy: Managing CRS and Building the Infrastructure Behind It

Safe Delivery of CAR-T and Bispecific Therapy: Managing CRS and Building the Infrastructure Behind It

October 30, 2026

CAR-T, Bispecifics, or Transplant: Sequencing Relapsed Diffuse Large B-Cell Lymphoma Therapy in 2026

CAR-T, Bispecifics, or Transplant: Sequencing Relapsed Diffuse Large B-Cell Lymphoma Therapy in 2026

Primary Refractory DLBCL: Choosing Between CAR-T and Bispecific Antibody Combinations

Primary Refractory DLBCL: Choosing Between CAR-T and Bispecific Antibody Combinations

Share Article

Get the Quick Bites delivered to your inbox daily

Binaytara logo

19-years of advocating, educating and innovating to improve Cancer Care.

Useful Links

  • News and Stories
  • OncoBlast
  • Careers
  • Donate

US Address

  • Binaytara
  • 3380 146th Pl SE, Suite 340
  • Bellevue, WA 98007 USA

Nepal Address

  • Binaytara Country Office
  • Kadam Chowk
  • Janakpur, NEPAL
  • _______
  • Binaytara Cancer Center
  • Janakpur, NEPAL

Legal

  • Privacy Policy

Binaytara is a 501(c)(3) not-for-profit organization. Our EIN number. is 26-1603676. © 2026, Binaytara. All rights reserved

Follow Binaytara on FacebookFollow Binaytara on BlueskyFollow Binaytara on LinkedinFollow Binaytara on YoutubeFollow Binaytara on TwitterFollow Binaytara on Instagram